Medtronic's CoreValve transcatheter aortic valve replacement system has won approval from the FDA months earlier than anticipated. The approval applies to patients who are ineligible for surgery to treat severe aortic stenosis. "The low rates of stroke and valve leakage with the CoreValve System –- two of the most concerning complications of valve replacement because they increase the risk of death and have a dramatic impact on quality of life –- set a new standard for transcatheter valves," researcher Dr. Jeffrey J. Popma said in a statement.

Full Story:

Related Summaries